跳至主要内容
临床试验/NCT00960336
NCT00960336已完成2 期

Multicenter Study of PEGylated Liposomal Doxorubicin in Geriatric Oncology - Metastatic Breast Cancer - First-line Treatment PEGylated Liposomal Doxorubicin in Patients Older Than 70 Years, Breast Cancer Metastasis

ARCAGY/ GINECO GROUP1 个研究点 分布在 1 个国家目标入组 59 人开始时间: 2008年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
59
试验地点
1
主要终点
Response rate

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well doxorubicin hydrochloride liposome works as first-line therapy in treating older women with metastatic breast cancer.

详细描述

OBJECTIVES:

Primary

  • Evaluate the effectiveness of pegylated liposomal doxorubicin hydrochloride, in terms of objective response rate, in elderly women with metastatic breast cancer.

Secondary

  • Determine the feasibility of this drug in these patients.
  • Evaluate chemotherapy-induced toxicities in these patients.
  • Assess the disease-free survival and overall survival of these patients.
  • Study the geriatric covariates.
  • Assess the covariates predictive of the hematopoietic reserve and the risk of febrile neutropenia in these patients.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
70 Years 至 —(Older Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

single arm

Experimental

干预措施: pegylated liposomal doxorubicin hydrochloride (Drug)

结局指标

主要结局

Response rate

时间窗: 3 and 6 cures

次要结局

未报告次要终点

研究者

发起方
ARCAGY/ GINECO GROUP
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验